All articles tagged with #zurzuvae
Jennifer Lawrence shares her postpartum struggles, including anxiety and feelings of inadequacy, which she experienced more intensely after her second child. She discusses her emotional challenges, her use of the drug Zurzuvae, and how her personal experience informed her portrayal of a new mother in her upcoming film 'Die My Love.'
Supernus Pharmaceuticals is acquiring Sage Therapeutics in a deal valued at up to $795 million, aiming to expand its neuropsychiatry portfolio with the FDA-approved postpartum depression treatment ZURZUVAE and to achieve significant growth and cost synergies by 2026.
The first oral pill approved in the United States to treat postpartum depression, called Zurzuvae, is now available by prescription. The medication, which costs $15,900 per course before insurance, has shown promising results in reducing depressive symptoms within three days and lasting through at least 45 days. However, concerns have been raised about the accessibility of the drug due to its high cost. Biogen and Sage Therapeutics, the drugmakers, have launched a patient support program to provide financial assistance and medication at no cost for eligible individuals. Other oral options for postpartum depression treatment, such as SSRIs, are significantly cheaper.
The first oral pill approved by the FDA to treat postpartum depression, called Zurzuvae, is now available in the US. The medication, which costs $15,900 per course before insurance, has shown promising results in reducing depressive symptoms within three days. However, concerns have been raised about its accessibility due to the high cost. Biogen and Sage Therapeutics have launched a patient support program to provide financial assistance and medication at no cost for eligible individuals. Other options for treating postpartum depression, such as SSRIs, are more affordable but take longer to take effect.
The first FDA-approved pill for postpartum depression, Zurzuvae, is set to hit the market next month with a price tag of nearly $16,000 for a two-week course of treatment. However, doctors argue that a better alternative already exists in the form of progesterone replacement therapy, which is safe, effective, and available for as low as 36 cents per capsule. They criticize the lack of individualized care for women's health in the US and highlight the rising maternal death rate in the country. Additionally, concerns are raised about the long-term effects and limited data on Zurzuvae, while bioidentical hormone therapy is touted as a superior option.
A newly approved medication called Zurzuvae, designed to treat postpartum depression, will cost $15,900 for a 14-day course before insurance. The high price has raised concerns about accessibility, as some patients may struggle to afford the drug. While the drug's manufacturers aim to provide financial assistance and ensure broad access, there are worries that insurance coverage may be limited, potentially creating barriers for patients. Postpartum depression affects a significant number of individuals, and Zurzuvae offers a fast-acting alternative to current treatment options. However, experts emphasize the importance of a combination of therapy and medication for comprehensive mental health care.
The FDA has approved Zurzuvae, the first pill to treat postpartum depression in adults, which is expected to be available in the fourth quarter of the year. Zurzuvae is reported to provide rapid relief compared to other depression medications, with noticeable changes in one to three doses. The side effects are minimal, and the medication is seen as a potential treatment option for postpartum depression, raising awareness about the condition.
A recovering addict reflects on her experience of self-medicating undiagnosed postpartum anxiety with Ambien, which eventually led to addiction. The recent FDA approval of Zurzuvae, a fast-acting oral medication specifically designed to treat postpartum depression, highlights the need for conversations and better treatment options for the 1 in 8 new moms affected by this condition. The author emphasizes the importance of addressing postpartum issues without stigma, as self-medication with substances can lead to tragic outcomes. The hope is that Zurzuvae is just the beginning of a trend towards better medications and support for new moms and their children.
The author shares her personal experience of self-medicating undiagnosed postpartum anxiety with Ambien, which eventually led to addiction. She highlights the lack of awareness and stigma surrounding postpartum issues, particularly among women of color. The recent FDA approval of Zurzuvae, a fast-acting oral medication for postpartum depression, is seen as a game-changer and an opportunity to start important conversations about a condition that affects many new moms. The author emphasizes the need for open dialogue and accessible treatments to help new mothers and prevent the risk of substance abuse.
The FDA has approved the first-ever pill, Zurzuvae (zuranolone), for treating postpartum depression, a potentially life-threatening condition that affects hundreds of thousands of new parents in the US each year. The pill, to be taken once a day for 14 days, has shown promising results in reducing symptoms of depression in two company studies, with some patients experiencing benefits as early as three days. The drug is expected to be commercially available in the fourth quarter of this year. However, the cost and accessibility of the drug remain uncertain. Medical experts and maternal health groups see it as a potentially game-changing option, but caution that it may not be the best choice for everyone and encourage women to consult with their healthcare provider for the best course of treatment.
The FDA has approved the first pill, Zurzuvae, specifically designed to treat severe depression after childbirth. Postpartum depression affects thousands of new mothers in the U.S. each year, and while standard treatments like counseling or antidepressants may not work for everyone, Zurzuvae has shown promising results in clinical trials. The pill, taken once a day for 14 days, has been found to reduce signs of depression within a few days for many patients. The drug's milder side effects and oral administration make it a beneficial option for women experiencing extreme postpartum depression.
The US Food and Drug Administration (FDA) has approved the first pill, zuranolone (sold as Zurzuvae), for the treatment of postpartum depression (PPD). Previously, PPD treatment was only available as an intravenous injection. Clinical trials showed that the pill significantly reduced depressive symptoms within three days, with effects lasting up to four weeks after the last dose. Common side effects include drowsiness, dizziness, and diarrhea. The medication can affect a person's ability to drive and perform hazardous activities, and patients are advised not to drive or operate heavy machinery for at least 12 hours after taking it. The manufacturers, Sage Therapeutics and Biogen, had also sought approval for the use of zuranolone in major depressive disorder (MDD), but the FDA determined that further studies were needed.
The FDA has approved the first pill, called Zurzuvae, specifically for the treatment of severe postpartum depression. The drug, to be taken once a day for two weeks, has shown positive results in reducing depression symptoms in women. Postpartum depression affects around 400,000 women each year, and Zurzuvae provides a beneficial oral medication option for those coping with extreme feelings. However, concerns remain about the long-term effects and cost of the drug.
The FDA has approved Zurzuvae (zuranolone), the first oral medication for postpartum depression (PPD) in adults. PPD is a major depressive episode that occurs after childbirth or during late pregnancy. Previously, treatment for PPD was only available as an IV injection. Zurzuvae demonstrated efficacy in two studies, showing significant improvement in depressive symptoms compared to placebo. However, the medication carries a boxed warning regarding its impact on driving and other potentially hazardous activities. Common side effects include drowsiness, dizziness, diarrhea, fatigue, and urinary tract infection. Zurzuvae may cause fetal harm, and effective contraception is recommended while taking the medication.